The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,259 | -1,984 | -1,483 | -4,761 |
| Depreciation | 3 | 3 | 4 | 17 |
| Reduction in the carrying amount of right-of-use assets | 121 | 182 | 103 | 196 |
| Share-based compensation | 113 | 85 | 77 | 268 |
| Allowance for doubtful accounts | - | 0 | 0 | 0 |
| Accounts receivable | - | 20 | -10 | 10 |
| Prepaid expenses and other current assets | -47 | 138 | -131 | -42 |
| Accounts payable | 247 | -365 | -213 | 741 |
| Accrued expenses and other current liabilities | 197 | -73 | -194 | 446 |
| Operating lease liability | -128 | -187 | -107 | -206 |
| Net cash used in operating activities | -1,659 | -2,497 | -1,672 | -3,267 |
| Purchase of property and equipment | 3 | 6 | 0 | 1 |
| Net cash used in investing activities | -3 | -6 | 0 | -1 |
| Exercise of common stock warrants | - | 5 | - | - |
| Taxes paid related to net share settlement of equity awards | - | 197 | - | - |
| Proceeds from sales of common stock | 225 | 0 | 6,783 | 1,907 |
| Issuance costs of sale of common stock | 108 | 96 | 804 | 30 |
| Net cash provided by financing activities | 117 | -288 | 5,979 | 1,877 |
| Net change in cash and cash equivalents | -1,545 | -2,791 | 4,307 | -1,391 |
| Cash and cash equivalents at beginning of year | 2,496 | 5,287 | 980 | 2,371 |
| Cash and cash equivalents at end of period | 951 | 2,496 | 5,287 | 980 |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)